GlassScriptPhysician profile
Elana L Sheldon
NPI 1790708915
$4,812.66
in general payments reported to CMS, 2019-2025
29 companies · $1,017 in 2025
The $1,017 reported for 2025 was more than what 85% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $403 · 2020: $370 · 2021: $300 · 2022: $744 · 2023: $1,024 · 2024: $955 · 2025: $1,017.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,996.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,995.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $517.82 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Abbvie INC. | $512.78 | 2020-2025 | Qulipta, Ubrelvy, Lo Loestrin Fe |
| Sanofi Pasteur INC. | $453.40 | 2019-2025 | |
| Lilly USA, LLC | $429.98 | 2019-2025 | Mounjaro, Zepbound |
| Bausch Health US, LLC | $387.22 | 2019-2025 | Aplenzin, Wellbutrin |
| Abbott Laboratories | $312.39 | 2022-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Glaxosmithkline, LLC. | $294.20 | 2022-2025 | Arexvy, Shingrix, Trelegy Ellipta |
| Astrazeneca Pharmaceuticals LP | $290.65 | 2019-2025 | Breztri, Farxiga |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $235.30 | 2019-2025 | Xifaxan, Trulance |
| Amgen INC. | $204.67 | 2020-2025 | Repatha, Otezla, Repatha |
| Exact Sciences Corporation | $154.29 | 2023-2025 | Cologuard Collection Kit |
| Pfizer INC. | $123.89 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $112.58 | 2023-2025 | Gardasil 9, Capvaxive, Gardasil |
| Hologic Sales and Service, LLC | $100.85 | 2019-2023 | Thinprep 2000 Processor, Aptima |
| Boehringer Ingelheim Pharmaceuticals, INC. | $99.75 | 2022-2023 | Jardiance |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceutical Holding Company LTD. | $97.95 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $92.45 | 2020-2021 | |
| Boston Scientific Corporation | $74.34 | 2021-2024 | |
| Phadia US INC. | $55.70 | 2019-2023 | Immunocap |
| Allergan, INC. | $39.45 | 2019 | |
| Axsome Therapeutics, INC. | $37.53 | 2025 | Symbravo |
| Biohaven Pharmaceuticals, INC. | $28.88 | 2021 | |
| Corcept Therapeutics | $28.86 | 2025 | Korlym |
| Mayne Pharma Commercial LLC | $28.65 | 2025 | |
| Amarin Pharma, INC. | $24.18 | 2020 | |
| Intra-Sana Laboratories | $21.47 | 2025 | Reltone 200 Mg, Reltone 400 Mg, Glycate |
| Astellas Pharma US INC | $18.87 | 2020 | |
| Shield Therapeutics INC | $18.65 | 2022 | |
| Azurity Pharmaceuticals, INC. | $15.91 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Elana Sheldon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.